QQQ   270.31 (-0.43%)
AAPL   450.91 (+1.45%)
MSFT   208.25 (-1.99%)
FB   263.00 (-2.03%)
GOOGL   1,496.82 (-0.10%)
AMZN   3,148.16 (-0.61%)
NVDA   446.60 (-0.31%)
CGC   17.93 (+7.82%)
BABA   248.13 (-1.57%)
TSLA   1,418.57 (-2.35%)
GE   6.67 (+4.22%)
MU   49.15 (+0.82%)
AMD   82.24 (-3.08%)
T   30.20 (+0.60%)
F   7.09 (+3.35%)
ACB   10.22 (-0.49%)
GILD   68.51 (-1.21%)
NFLX   483.38 (-2.29%)
DIS   128.79 (-0.88%)
BAC   26.56 (+1.72%)
BA   179.41 (+5.52%)
QQQ   270.31 (-0.43%)
AAPL   450.91 (+1.45%)
MSFT   208.25 (-1.99%)
FB   263.00 (-2.03%)
GOOGL   1,496.82 (-0.10%)
AMZN   3,148.16 (-0.61%)
NVDA   446.60 (-0.31%)
CGC   17.93 (+7.82%)
BABA   248.13 (-1.57%)
TSLA   1,418.57 (-2.35%)
GE   6.67 (+4.22%)
MU   49.15 (+0.82%)
AMD   82.24 (-3.08%)
T   30.20 (+0.60%)
F   7.09 (+3.35%)
ACB   10.22 (-0.49%)
GILD   68.51 (-1.21%)
NFLX   483.38 (-2.29%)
DIS   128.79 (-0.88%)
BAC   26.56 (+1.72%)
BA   179.41 (+5.52%)
QQQ   270.31 (-0.43%)
AAPL   450.91 (+1.45%)
MSFT   208.25 (-1.99%)
FB   263.00 (-2.03%)
GOOGL   1,496.82 (-0.10%)
AMZN   3,148.16 (-0.61%)
NVDA   446.60 (-0.31%)
CGC   17.93 (+7.82%)
BABA   248.13 (-1.57%)
TSLA   1,418.57 (-2.35%)
GE   6.67 (+4.22%)
MU   49.15 (+0.82%)
AMD   82.24 (-3.08%)
T   30.20 (+0.60%)
F   7.09 (+3.35%)
ACB   10.22 (-0.49%)
GILD   68.51 (-1.21%)
NFLX   483.38 (-2.29%)
DIS   128.79 (-0.88%)
BAC   26.56 (+1.72%)
BA   179.41 (+5.52%)
QQQ   270.31 (-0.43%)
AAPL   450.91 (+1.45%)
MSFT   208.25 (-1.99%)
FB   263.00 (-2.03%)
GOOGL   1,496.82 (-0.10%)
AMZN   3,148.16 (-0.61%)
NVDA   446.60 (-0.31%)
CGC   17.93 (+7.82%)
BABA   248.13 (-1.57%)
TSLA   1,418.57 (-2.35%)
GE   6.67 (+4.22%)
MU   49.15 (+0.82%)
AMD   82.24 (-3.08%)
T   30.20 (+0.60%)
F   7.09 (+3.35%)
ACB   10.22 (-0.49%)
GILD   68.51 (-1.21%)
NFLX   483.38 (-2.29%)
DIS   128.79 (-0.88%)
BAC   26.56 (+1.72%)
BA   179.41 (+5.52%)
Log in

NASDAQ:IDXXIDEXX Laboratories Stock Price, Forecast & News

$377.19
-4.57 (-1.20 %)
(As of 08/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$376.16
Now: $377.19
$382.29
50-Day Range
$314.67
MA: $351.76
$397.75
52-Week Range
$168.65
Now: $377.19
$407.86
Volume621,900 shs
Average Volume599,510 shs
Market Capitalization$32.08 billion
P/E Ratio71.30
Dividend YieldN/A
Beta0.85
IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.
Read More
IDEXX Laboratories logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.19 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:IDXX
CUSIP45168D10
Phone207-556-0300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.41 billion
Cash Flow$5.94 per share
Book Value$2.07 per share

Profitability

Net Income$427.72 million

Miscellaneous

Employees9,200
Market Cap$32.08 billion
Next Earnings Date10/29/2020 (Estimated)
OptionableOptionable
$377.19
-4.57 (-1.20 %)
(As of 08/10/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IDXX News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions

How has IDEXX Laboratories' stock been impacted by COVID-19 (Coronavirus)?

IDEXX Laboratories' stock was trading at $245.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IDXX stock has increased by 53.6% and is now trading at $377.19.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of IDEXX Laboratories?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for IDEXX Laboratories
.

When is IDEXX Laboratories' next earnings date?

IDEXX Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for IDEXX Laboratories
.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) issued its quarterly earnings results on Friday, July, 31st. The company reported $1.72 earnings per share for the quarter, topping analysts' consensus estimates of $1.17 by $0.55. The company had revenue of $637.20 million for the quarter, compared to analysts' expectations of $589.98 million. IDEXX Laboratories had a net margin of 18.59% and a return on equity of 241.52%. IDEXX Laboratories's quarterly revenue was up 2.8% on a year-over-year basis. During the same quarter last year, the company earned $1.43 EPS.
View IDEXX Laboratories' earnings history
.

How will IDEXX Laboratories' stock buyback program work?

IDEXX Laboratories declared that its Board of Directors has initiated a stock repurchase program on Wednesday, February 12th 2020, which authorizes the company to buyback 5,000,000 outstanding shares, according to EventVestor. This buyback authorization authorizes the company to buy shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company's leadership believes its stock is undervalued.

What price target have analysts set for IDXX?

5 equities research analysts have issued 1 year target prices for IDEXX Laboratories' stock. Their forecasts range from $277.00 to $415.00. On average, they expect IDEXX Laboratories' stock price to reach $353.40 in the next year. This suggests that the stock has a possible downside of 6.3%.
View analysts' price targets for IDEXX Laboratories
.

Has IDEXX Laboratories been receiving favorable news coverage?

News articles about IDXX stock have been trending somewhat negative this week, InfoTrie reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. IDEXX Laboratories earned a news sentiment score of -1.9 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
View the latest news about IDEXX Laboratories
.

Are investors shorting IDEXX Laboratories?

IDEXX Laboratories saw a decline in short interest during the month of July. As of July 31st, there was short interest totaling 1,590,000 shares, a decline of 17.6% from the July 15th total of 1,930,000 shares. Based on an average daily trading volume, of 511,600 shares, the short-interest ratio is presently 3.1 days. Approximately 1.9% of the company's shares are sold short.
View IDEXX Laboratories' Short Interest
.

Who are some of IDEXX Laboratories' key competitors?

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Alibaba Group (BABA), Paypal (PYPL), Netflix (NFLX), Mastercard (MA), Adobe (ADBE), Intuitive Surgical (ISRG), salesforce.com (CRM), Walt Disney (DIS) and Home Depot (HD).

Who are IDEXX Laboratories' key executives?

IDEXX Laboratories' management team includes the following people:
  • Mr. Jonathan W. Ayers, Chairman, CEO & Pres (Age 63)
  • Mr. Brian P. McKeon, CFO, Exec. VP & Treasurer (Age 57)
  • Ms. Jacqueline L. Studer, Corp. VP, Gen. Counsel & Corp. Sec. (Age 60)
  • Mr. Giovani Twigge, Chief HR Officer & Corp. VP (Age 55)
  • Mr. Jay Mazelsky, Exec. VP of Companion Animal Group (Age 58)

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Principal Financial Group Inc. (1.46%), Sumitomo Mitsui Trust Holdings Inc. (0.42%), Swiss National Bank (0.40%), Robeco Institutional Asset Management B.V. (0.32%), Congress Asset Management Co. MA (0.28%) and Frontier Capital Management Co. LLC (0.25%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Giovani Twigge, Jacqueline Studer, James F Polewaczyk, Jay Mazelsky, Jonathan W Ayers, Lawrence D Kingsley, M Anne Szostak, Michael Lane, Rebecca M Henderson and Sophie V Vandebroek.
View institutional ownership trends for IDEXX Laboratories
.

Which major investors are selling IDEXX Laboratories stock?

IDXX stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Robeco Institutional Asset Management B.V., Ardevora Asset Management LLP, Oregon Public Employees Retirement Fund, Rafferty Asset Management LLC, State of Alaska Department of Revenue, Amalgamated Bank, and Trust Co. of Vermont. Company insiders that have sold IDEXX Laboratories company stock in the last year include Giovani Twigge, James F Polewaczyk, Jonathan W Ayers, M Anne Szostak, and Rebecca M Henderson.
View insider buying and selling activity for IDEXX Laboratories
.

Which major investors are buying IDEXX Laboratories stock?

IDXX stock was purchased by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Frontier Capital Management Co. LLC, Capital Investment Services of America Inc., Envestnet Asset Management Inc., Riverbridge Partners LLC, Victory Capital Management Inc., Candriam Luxembourg S.C.A., and Fisher Asset Management LLC.
View insider buying and selling activity for IDEXX Laboratories
.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IDEXX Laboratories' stock price today?

One share of IDXX stock can currently be purchased for approximately $377.19.

How big of a company is IDEXX Laboratories?

IDEXX Laboratories has a market capitalization of $32.08 billion and generates $2.41 billion in revenue each year. The company earns $427.72 million in net income (profit) each year or $4.89 on an earnings per share basis. IDEXX Laboratories employs 9,200 workers across the globe.

What is IDEXX Laboratories' official website?

The official website for IDEXX Laboratories is www.idexx.com.

How can I contact IDEXX Laboratories?

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]

This page was last updated on 8/10/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.